Skip to main content
Fig. 4 | EJNMMI Research

Fig. 4

From: [18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial

Fig. 4

Eleven-year-old girl diagnosed with left distal femur osteosarcoma. PET-1 (ad) showed stage IIa localized [18F]FDG avid disease (SUVmax 15.2; MTV 113.2 mm3; TLG 84.4). Non sarcoma related [18F]FDG uptake was visualized in the thymus (physiologic), the right adnexa (physiologic) and the right piriformis muscle (functional or strain). PET-2 (eh) showed decreased [18F]FDG uptake (SUVmax 2.2; MTV 83.9 mm3; 46.1) after neo-CTX. Diffuse [18F]FDG uptake in bone marrow (h), was related to rebound post-CTX. Patient underwent surgery (necrosis > 99%) and had no evidence of disease (NED) at last follow-up. PET1, a PET 3D MIP, b fused PET/CT axial view, c fused PET/CT sagittal view, d CT sagittal view. PET2, e Fused PET/CT axial view, f fused PET/CT sagittal view, g CT sagittal view, h PET 3D MIP

Back to article page